BeOne Medicines (ONC) Depreciation & Amortization (CF) (2016 - 2026)

BeOne Medicines (ONC) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $40.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 13.76% year-over-year to $40.5 million in Q2 2026; TTM through Jun 2026 was $154.9 million, a 18.44% decrease from a year earlier, with the FY2025 full-year figure at $141.7 million, down 17.51% from the prior year.
• Depreciation & Amortization (CF) was $40.5 million for Q2 2026 at BeOne Medicines, down from $41.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $71.3 million in Q3 2024 and troughed at $15.5 million in Q2 2022.
• A 5-year average of $30.5 million and a median of $25.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 231.44% in 2024 and slumped 47.7% in 2025, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $18.0 million in 2022, then jumped by 32.21% to $23.8 million in 2023, then jumped by 110.95% to $50.2 million in 2024, then dropped by 28.38% to $36.0 million in 2025, then rose by 12.59% to $40.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $40.5 million (Q2 2026), $41.1 million (Q1 2026), and $36.0 million (Q4 2025), per Business Quant data.